Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03387163 · ClinicalTrials.gov registry record
Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 402
- Enrollment target
NCT03387163 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 402 participants.
The verdict
NCT03387163 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 402 participants
- Enrollment target
Study Summary
Real-world evidence of the clinical course of patient symptoms following initiation of sacubitril/valsartan via PROs with a patient-centered study design will provide important evidence of potentially beneficial outcomes associated with the use of this therapy.
Interventions
- DRUG Sacubitril/Valsartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2018-02-09 |
| Est. Completion | 2019-06-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03387163
The ClinicalTrials.gov registry entry for NCT03387163 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 402 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sacubitril/Valsartan is the first listed.
NCT03387163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03387163 about?
NCT03387163 is a clinical study titled "Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure". Real-world evidence of the clinical course of patient symptoms following initiation of sacubitril/valsartan via PROs with a patient-centered study design will provide important evidence of potentially beneficial outcomes associated with the use of this therapy.
What is the current status of trial NCT03387163?
This trial is currently completed. The enrollment target is 402 participants. The study started on 2018-02-09. Estimated completion is 2019-06-21.
What interventions are being tested in trial NCT03387163?
The interventions under investigation include: Sacubitril/Valsartan (DRUG).
Who is sponsoring clinical trial NCT03387163?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.